Remifentanil TIVA

Phase 2Small molecule

Remifentanil TIVA is one of 8 small molecule programs targeting Adolescent Idiopathic Scoliosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adolescent Idiopathic ScoliosisActive, not recruiting

Adolescent Idiopathic ScoliosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Adolescent Idiopathic Scoliosis

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 2

Duragesic

CCephalon

Approved

1 3

Dysport

GGalderma R&D

Approved

1 4

Decadron

AAspen Global Incorporated

Approved

1 5

Cyklokapron

AAmring

Approved

—6

Lignocaine

UUniversity of Malaya

Approved

1 7

Marcaine

IInnocoll

Preclinical

1 8

Remifentanil TIVA

CCedars-Sinai Medical Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adolescent Idiopathic Scoliosis1 trial

Propofol + Remifentanil vs. Propofol + Dexmedetomidine in Adolescent Idiopathic Scoliosis Patients Having Spine Surgery

Terminated·—·Phase 2·NCT06096181·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Remifentanil TIVA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Remifentanil TIVA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Remifentanil TIVA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cedars-Sinai Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCedars-Sinai Medical Center

Remifentanil TIVA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adolescent Idiopathic Scoliosis1 trial

References

Drug Info

Quick Facts

Related News